Although heterozygous duplications of TP53 are rare events, they may co-occur with IDH1 mutations, a combination that is generally associated with worse clinical outcomes, although the magnitude and biological context of this effect depend on the tumor type and the allelic status of TP53 (28, 29). Here, TP53 is linked to neoplasm.